Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Trinean to Enter into Global Supply Agreement with QIAGEN

Published: Tuesday, January 21, 2014
Last Updated: Tuesday, January 21, 2014
Bookmark and Share
Trinean to manufacture and supply the QIAxpert - a micro-volume spectrometer for DNA and RNA quantitation and quality analysis.

Trinean has announced that it has entered into a manufacturing and supply agreement with QIAGEN for the production of the QIAxpert, a micro-volume spectrometer for DNA and RNA quantitation and quality analysis.

This platform is a UV/VIS spectrophotometer which contains tailor-made solution for QIAGEN customers using QIAGEN’s DNA and RNA sample technologies and devices for quality control applications.

“We are very pleased with this agreement between QIAGEN and Trinean,” comments Philippe Stas, CEO of Trinean. "Adoption of our technology by QIAGEN, the market leader in DNA and RNA sample technologies, is an important new step in the global validation of our innovative take on UV-VIS spectroscopy.”

“Quality control (QC) is becoming increasingly important in nucleic acid based testing as novel detection technologies become more and more sensitive.” Dietrich Hauffe, Senior VP ,Head of Business Area Life Sciences at QIAGEN adds.

“The QIAxpert system provides a unique combination of accurate quantification and the capability to discriminate between molecules of interest. The system allows us to match high-performance sample technologies, in particular isolation, extraction and purification with high-speed spectrophotometry for confirmatory purposes. It will contribute to superior data output across all analytical workflows using DNA or RNA, from PCR to next generation sequencing. QIAxpert can also allow our customers to make better informed decisions with regards to usage of samples in subsequent downstream processes, reducing the risk of repeat experiments. These benefits can result in significant time and cost savings while at the same time increasing the quality of data output with significant advantages in research, applied and clinical markets.”

“This agreement significantly boosts the market reach of our spectrometry technology”, said Yvan Sergeant, VP Commercial Operations of Trinean. “It combines microfluidics with innovative spectral content profiling software for accurate quantitation of biological samples and further illustrates the importance of our ability to have a sound purity check of biological samples prior to any genetic test.”

The QIAxpert is a customized version of the Xpose reader, launched by Trinean early 2013. The platform redefines manual UV/VIS quantification into a convenient, high speed solution. The drop and read approach avoids time-consuming sample loading and cleaning steps thereby minimizing the hands-on time on the reader.

The full-color touch screen gives single touch access to advanced analytical software, including dye-free specific quantification of DNA, RNA or protein in samples containing interfering components, using Trinean’s proprietary algorithms for UV/VIS spectral deconvolution.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Trinean to be Awarded ISO 9001:2008 Certification
Certification awarded for Trinean’s Quality Management System.
Tuesday, February 03, 2015
Trinean to Appoint New Board Member
Company announced that it appointed Mr Chris van Ingen as independent board member.
Friday, May 02, 2014
Trinean Signs a Global Agreement with Bayer CropScience
Bayer will use Trinean’s technology for biomolecule QC using spectral content profiling.
Wednesday, June 12, 2013
Trinean Secures 1 Million Euro Financing
Capricorn Health-tech Fund to join the investor base.
Wednesday, May 29, 2013
Trinean Appoints New CEO and Secures 2.7 Million Euro Financing
Appointment of Philippe Stas as Company’s new CEO.
Monday, April 30, 2012
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!